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Introduction: Statins, hydroxymethylglutaryl-coenzyme A reductase 
inhibitors, have been reported to have anti-inflammatory and/or 
immunomodulatory effects, and prophylactic and therapeutic effects in 
collagen induced arthritis -an experimental model of rheumatoid arthritis 
(RA). Here, the authors undertook to determine the effect of atorvastatin 
on the expressions of osteoprotegerin (OPG) and receptor activator of 
nuclear factor κB ligand (RANKL) in RA fibroblast-like synoviocytes 
(RA-FLSs), to identify the mechanisms responsible for these effects, and 
to determine whether the statin inhibit osteoclastogenesis. 
Methods: FLSs isolated from five RA patients were cultured in the 
presence of 20 ng/ml of TNF-α with or without atorvastatin. RANKL 
expressions were assayed by Western blotting and enzyme-linked 
immunosorbent assay. RANKL, RANK and OPG expression were 
assayed by reverse transcription-polymerase chain reaction (RT-PCR). 
Osteoclast formation was assayed by counting cells after staining for 
tartrate-resistant acid phosphatase in cocultures of peripheral blood 
mononuclear cells (PBMCs) and RA FLSs. 
Results: Atorvastatin inhibited the expression of RANKL in RA FLSs in 
a dose-dependent manner, and the suppression of RANKL was 
prevented by mevalonate. However, OPG expression was not affected 




expression in CD14+ cells. On the other hand, atorvastatin suppressed 
TNF-α induced p38 phosphorylation in RA-FLSs and significantly 
reduced TRAP-positive multinucleated osteoclast formation in the 
coculture of PBMCs and RA-FLSs.  
Conclusion: These results suggest that atorvastatin inhibits 
osteoclastogenesis and bone destruction in RA patients.  
 
This work was published in Arthritis Research & Therapy Journal 
(Arthritis Research & Therapy 2012 Aug 17;14(4):R187). 
 
Keywords : Atorvastatin, Rheumatoid arthritis, Synoviocytes, RANKL, 
Osteoclastogensis. 
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Receptor activator of nuclear factor κB ligand (RANKL), and its 
receptor, RANK, have been found to be key factors in the stimulation of 
osteoclast formation, and they have also been suggested to play major 
roles in inflammation-induced bone loss and joint destruction in arthritis 
[1, 2]. The soluble tumor necrosis factor (TNF) receptor molecule, 
osteoprotegerin (OPG), is a natural inhibitor of RANKL. OPG binds to 
RANKL and prevents it from interacting with RANK, and thus, the 
balance between RANKL and OPG in the bone microenvironment 
regulates bone resorption [3].  
Rheumatoid arthritis (RA) is characterized by inflammatory synovitis 
and progressive destruction of joint cartilage and bone [4, 5]. 
Furthermore, RA patients exhibit high serum levels of OPG and soluble 
RANKL [6], RANKL mRNA is present in the synovial lining layer in 
RA [7]. However, RANKL is not expressed in normal synovium, which 
suggests a link between RANKL expression and the development of 
synovial lesions in RA [8]. In addition, recent studies have provided 
genetic evidence that RANKL and osteoclasts are central players in the 
inflammatory destruction of bone [9], and that enhanced RANKL 
expression in synoviocytes induced by synovial inflammation may be 
critical for osteoclastogenesis [10].  




inhibitors, constitute a family of chemically related molecules with 
lipid-lowering effects. Statins are extensively used in medical practice, 
and large-scale clinical trials have demonstrated their efficacies at 
reducing cardiovascular-related morbidities and mortalities [11, 12]. 
Furthermore, increasing clinical and experimental evidence indicates 
that statins might have general anti-inflammatory and 
immunomodulatory effects, whereas research studies conducted over the 
last 10 years have elucidated a number of mechanisms by which statins 
may exert anti-inflammatory effects [13, 14]. More recently, the 
beneficial effects of statins have been extended to the direct 
immunomodulation of monocyte-mediated inflammatory processes 
(including chronic inflammatory diseases, such as, atherogenesis and 
RA), independently of their effects on cholesterol levels [15-17]. 
Atorvastatin has been shown to have anti-inflammatory potential in RA 
clinical trials [18, 19]. However, the effects of atorvastatin on human 
osteoclasts have not been determined. In this study, we examined the 
effects of atorvastatin on the expressions of OPG and RANKL in 
fibroblast-like synoviocytes (FLSs) from RA patients and the 
mechanisms involved, and in addition, we sought to determine whether 







Materials and methods 
Chemicals 
Atorvastatin (Pfizer, New York, NY) was prepared as a suspension in 
dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO). Mevalonate 
(Sigma) was dissolved in 1N NaOH (pH 7.1). SB2035820, p38 inhibitor, 
was purchased from Cell Signaling Technology (Danvers, MA). 
 
Primary culture of FLS  
Synovial tissues were obtained from five patients undergoing joint 
replacement surgery. All five patients fulfilled the 2010 rheumatoid 
arthritis classification criteria of RA by the American College of 
Rheumatology/European League Against Rheumatism collaborative 
initiative [20]. This study was approved by Institutional Review Board 
and informed consent was obtained from all patients. Their clinical 
characteristics are shown in Table 1. 
Synovial tissues were washed with phosphate buffered saline (PBS), 
minced and digested for 2 hours at 37°C in Dulbecco’s Modified Eagle’s 
Medium-High Glucose (DMEM-HG; JBI, Korea) containing 1 mg/ml 
type II collagenase (Worthington biochemical corporation, NJ). The 
digested tissues were filtered through a 70-μm cell strainer (Becton 
Dickinson, Franklin Lakes, NJ). Cell suspensions were centrifuged at 




resuspended in DMEM-HG containing 1% penicillin-streptomycin 
(Gibco/BRL, Grand Island, NY) and 10% heat-inactivated fetal bovine 
serum (FBS; Gibco/BRL). The cells were then plated in 100-mm culture 
dish (Becton Dickinson) and incubated in a humidified 5% CO2 
atmosphere. Upon reaching confluence, cells were detached with 0.1% 
trypsin-EDTA (Gibco/BRL) and split in 5 × 105 cells per dish. For all 
experiments, 3-5 passage synovial fibroblasts were used.  
 
Immunomagnetic selection of CD14+ cells  
CD14+ cells were purified by MACS according to the manufacturer’s 
instructions (Miltenyi Biotech, Auburn, California). Briefly, 107 PBMCs 
were resuspended in 80 μl of cold PBS containing 0.5% BSA and 2 mM 
EDTA (MACS buffer). Microbeads (20 μl) conjugated with mouse anti-
human CD14IgG2a (Miltenyi Biotech) were then added to cells and 
incubated for 15 minutes at 4°C. Cells were then washed and 
resuspended in 3 ml of MACS buffer and then applied to a pre-
equilibrated sterile LS separation column (Miltenyi Biotech) placed in a 
MidiMACS magnet. The column was then washed three times with 
MACS buffer, and CD14+ cells were eluted with 5 ml of MACS buffer 
after removing the column from the magnet.  
 
Methylthiazol tetrazolium (MTT) assay 




Dickinson) and treated with M-CSF (2 ng/ml), 1,25-dihydroxyvitamin 
D3 (10
-7 M), atorvastatin for 24 hours (10-100 μM) or 3 weeks (0.001-0.1 
μM) in a 5% CO2 incubator. MTT labeling reagent (500 μg/ml;Sigma) 
was added to RA-FLSs or PBMCs in wells and incubated for 2 hours at 
37°C. Isopropanol supplemented with 0.4 M HCl was then added to 
release formazan dye from cells. Formazan absorbance in solution was 
measured using a microtiter-plate enzyme-linked immunosorbent assay 
(ELISA) reader at 570 nm. 
 
Propidium iodide (PI) staining 
FLSs were cultured in 100-mm culture dishes and treated with TNF-α 
(20 ng/ml), atorvastatin (10-100 μM) for 24 hours. Cells were harvested 
using 0.1% trypsin-EDTA, washed twice in PBS containing 0.1% 
(wt/vol) NaN3, and then 1 ml of cold 70% (vol/vol) ethanol was added 
to cell pellets. Cells were then vortexed and incubated at 4°C for 1 hour, 
washed twice, and resuspended in 0.1 ml of PBS containing 0.1% NaN3. 
For DNA staining, cells were treated with 1 mg/ml of RNase A (Sigma), 
resuspended in 0.5 ml of PBS containing 50 mg/ml PI (Sigma), and 
incubated for 30 minutes at 4°C in the dark. They were then analyzed by 
flow cytometry (FACS Caliber, BD Science), and the sub-G0/G1 
portion (the M1 fraction) was considered to be the apoptotic fraction. 
 





Total RNA was extracted from FLSs or CD14+ cells by using TRIzol 
reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according 
to the manufacturer's instructions. In brief, FLSs or CD14+ cells were 
cultured in six-well plates in the presence or absence of TNF-α (20 
ng/ml), atorvastatin for FLSs (10 to 100 μM), for CD14+ cells (0.01 to 1 
μM) for 24 to 72 hours. The cells were then lysed by adding 1 ml TRIzol 
reagent, and lysates were collected in 1.5-ml microtubes, to which was 
added 0.2 ml of chloroform (Sigma). The microtubes were then 
centrifuged at 12,000 g for 15 minutes at 4°C, and supernatants were 
transferred to new microtubes. Isopropyl alcohol (0.5 ml) was then 
added to precipitate RNA, and microtubes were centrifuged at 12,000 g 
for 8 minutes at 4°C. Pellets were washed with 75% ethanol, dried at 
room temperature, and resuspended in 10 to 20 μl nuclease-free water 
(Applied Biosystems/Ambion, Austin, TX, USA). RNA concentrations 
were determined by measuring absorbance at 260 nm.  
First-strand cDNA was synthesized by using a Power cDNA Synthesis 
Kit (Intron Biotechnology, Seongnam, South Korea). The reaction was 
conducted in 20 μl of buffer containing 1 μg of total RNA, 0.2 mM oligo 
(dT)15 primer, 5× RT buffer, 40 mM DTT, 10 units of RNase inhibitor, 
2.5 mM deoxynucleotide triphosphate (dNTP) mixture, and 5 units of 
AMV reverse transcriptase. After incubation at 37°C for 1 hour, the 




remaining RNA, 1 μl of Escherichia coli RNase H (4 mg/ml) was added 
to reaction mixtures and this was followed by incubation at 37°C for 30 
minutes. The housekeeping gene, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), was used as an internal control for 
determining gene expression. The primers used to detect RANKL (S, 5' 
GCC AGT GGG AGA TGT TAG 3'; AS, 5' TTA GCT GCA AGT TTT 
CCC 3'); RANK (S, 5' TTA AGC CAG TGC TTC ACG GG 3'; AS, 5' 
ACG TAG ACC ACG ATG ATG TCG C 3'); OPG (S, 5' TGC TGT 
TCC TAC AAA GTT TAC C 3'; AS, 5' CTT TGA GTG CTT TAG 
TGC GTG 3'), and GAPDH (S, 5' GCT CTC CAG AAC ATC ATC CC 
3'; AS, 5' CGT TGT CAT ACC AGG AAA TG 3').  
PCR amplification of cDNA was performed in an automated thermal 
cycler (GeneAmp PCR System 2400, Applied Biosystems) in a final 
volume of 20 μl containing 1 to 4 μl of cDNA, 20 mM Tris-HCl (pH 
8.4), 50 mM KCl, 1.5 mM MgCl2, 0.1% Triton X-100, 0.2 mM dNTP 
mixture, 0.5 pmol of each primer, and 5 units of Taq DNA polymerase 
(Promega). After PCR, the amplified products were analyzed with 
electrophoresis in 1.5% agarose gel and visualized with ethidium 
bromide staining under UV illumination. Band intensities of PCR 
products were measured by using a UV/VIS Vilber Lourmat digital 
camera and the software BioCaptMW (Vilber Lourmat, Marne-la-Vallée, 
France).  




system (Applied Biosystems). Total RNA was extracted by using an 
RNeasy kit (Qiagen, Valencia, CA, USA). Synthesis of cDNA was 
performed by using an SuperScript III First-Strand Synthesis System 
(Invitrogen) according to the manufacturer's protocol. Quantitative real-
time PCR was performed by running a QuantiTect SYBR Green PCR 
Kit (Qiagen). Primer sequences were as follows; GAPDH, forward: 
CAATGACCCCTTCATTGACC; GAPDH, reverse: 
TGGACTCCACGACGTACTCA; and RANKL, forward 
GCTTGAAGCTCAGCCTTTTG:; and RANKL, reverse: 
CGAAAGCAAATGTTGGCATA. The reactions were incubated at 
94°C for 15 minutes for one cycle, and then at 94°C (15 seconds), 59°C 
(30 seconds), and 72°C (30 seconds) for 40 cycles. The quantity of 
mRNA was calculated by using the threshold cycle (Ct) value for 
amplification of human RANKL and for human GAPDH as a reference 
gene. Relative gene expression was determined by the 2ΔΔCt method.  
 
Western blot analysis 
Protein expressions were measured with Western blotting. In brief, 
cells were washed twice with ice-cold PBS, scraped into microfuge 
tubes, pelleted by centrifugation, and suspended in PRO-PREP protein-
extraction buffer (Intron). After 30 minutes of incubation on ice, 
samples were centrifuged at 14,000 rpm for 30 minutes at 4°C. Protein 




(Bio-Rad) with bovine serum albumin as a standard. Sodium 
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
carried out by using a mini-protein system (Bio-Rad). Dissolved protein 
samples were combined with sample buffer (125 mM Tris (pH 6.8), 5% 
glycerol, 2% SDS, 1% 2-mercaptoethanol, and 0.006% bromophenol 
blue) boiled for 5 minutes, and immediately cooled. Equivalent amounts 
of protein samples (50 μg/lane) were loaded onto 12% SDS gels. 
Electrophoresis was carried out in a running buffer at 100 V for 2 hours. 
Proteins were transferred from gels onto polyvinylidene difluoride 
(PVDF) membranes (Millipore, Bedford, MA, USA; 90 minutes at 30 
V) in transfer buffer (192 mM glycine, 25 mM Tris-HCl, pH 8.3, 0.02% 
SDS, and 20% vol/vol TBS-Tween buffer (20 mM Tris, pH 8.0, 150 mM 
NaCl, and 0.1% Tween 20)) for 1 hour at 4°C. After blocking with 5% 
nonfat dried milk in TBS-Tween buffer for 1 hour, rabbit polyclonal 
antibody to human RANKL (R&D), rabbit monoclonal anti-
Akt/phospho-Akt, anti-ERK/phospho-ERK, anti-JNK/phospho-JNK, 
anti-p38/phospho-p38 antibodies (all from Cell Signaling Technology), 
and rabbit monoclonal anti-actin antibody (Sigma) were added and 
incubated for 12 hours. Membranes were then washed and incubated 
with HRP-conjugated goat anti-rabbit IgG polyclonal antibodies 
(1:1,000; Jackson Immunoresearch, Philadelphia, PA, USA). 
Chemiluminescent substrate (Amersham Life Science, Arlington 




minutes. Blots were then exposed to radiographic film.  
 
 Enzyme-linked immunosorbent assay (ELISA)  
The secretion of sRANKL was detected using RANKL ELISA kit 
(Peprotech), according to the manufacturer’s directions. 
 
Coculture system for osteoclastogenesis  
Blood was collected from healthy volunteers, and PBMCs were 
isolated by centrifugation over Ficoll/Paque at 1,700 rpm for 30 minutes. 
PBMCs were resuspended in α-MEM containing 10% FBS and 2 ng/ml 
M-CSF (Sigma) and seeded at 2 × 105 cells/well in 96-well culture plates. 
On the following day, FLSs were added at 2 × 104 cells/well to adherent 
PBMCs and cocultured for 3 weeks in α-MEM containing 10% FBS, 
100 IU/ml benzyl penicillin, 100 mg/ml streptomycin, 2 ng/ml M-CSF, 
and 10-7 M 1,25-dihydroxyvitamin D3. The culture medium was replaced 
every 3 days. Adherent cells were stained for tartrate-resistant acid 
phosphatase (TRAP) by using a commercially available kit (Sigma), as 
previously described (10). TRAP-positive multinucleated cells 
containing three or more nuclei were identified as osteoclasts and 






Statical analysis  
Data are presented as mean ± SD. Statistical analysis was performed 
using SPSS version 12 (SPSS Inc., Chicago, IL, USA), and P values of 
























Effects of atorvastatin on RANKL in the FLSs of RA patients 
FLSs were cultured for 24 hours with atorvastatin in the presence of 
TNF-α (20 ng/ml), and assayed for RANKL expression with RT-PCR 
and real-time PCR. Atorvastatin significantly and dose-dependently 
inhibited the expression of RANKL mRNA in the FLSs of RA patients 
(P < 0.05) (Figure 1A, B). Western blotting of these cells showed that 
atorvastatin also dose-dependently suppressed RANKL protein levels 
(Figure 1C). Simvastatin has been reported to reduce arthritis incidence, 
activity, and histologic scores in a collagen-induced arthritis model, and 
simvastatin has been shown to have antiinflammatory potential in RA 
patients (18,22). Therefore, we determined whether simvastatin inhibits 
the expression of RANKL. Simvastatin also significantly and dose-
dependently inhibited the expression of RANKL mRNA and protein in 
the FLSs of RA patients (Figure 2). To determine the most effective time 
for TNF-α stimulation, RANKL expression was analyzed with RT-PCR 
after treating the FLSs of RA patients for 24 to 48 hours with TNF-α (20 
ng/ml). RANKL mRNA expression was found to peak after 24 hours of 
stimulation with TNF-α (20 ng/ml) (Figure 1D). Because mevalonate is 
synthesized from 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
by HMG-CoA reductase, HMG-CoA reductase inhibitors, like statins, 




To determine whether mevalonate prevents the inhibition of RANKL 
expression by atorvastatin, mevalonate (100 μM) was cotreated with 
atorvastatin. RT-PCR and Western blotting showed that mevalonate 
prevented the suppression of RANKL expression by atorvastatin (Figure 
3). Also, mevalonate prevented the inhibition of RANKL expression by 
simvastatin (Figure 4).  
 
The effects of atorvastatin on cell viability and apoptosis 
The effect of atorvastatin on cell viability was determined by using an 
MTT-based assay (Figure 5A). Apoptosis was measured by staining with 
propidium iodide (Figure 5B). Neither cell viability nor apoptosis was 
affected by atorvastatin at concentrations of 10 to 100 μM. Simvastatin 
did not affect cell viability and apoptosis (Figure 6).  
 
Effects of atorvastatin on OPG in the FLSs of RA patients 
The expressions of OPG mRNA were examined in FLSs from patients 
cultured for 24 hours with RT-PCR. Atorvastatin did not affect OPG 
expression in these cells (Figure 7A). We also assayed the secretion of 
OPG into the conditioned media of FLSs cultured in the presence of 
atorvastatin, and the statin was not found to affect OPG secretion (data 





Effect of atorvastatin on RANK in CD14+ cells  
The effect of atorvastatin on RANK in osteoclast precursor cells was 
evaluated by purifying CD14+ cells from total PBMCs by using a 
magnetic cell-separation (MACS) system. Atorvastatin did not affect 
RANK mRNA expression in CD14+ cells (Figure 7B), and the viabilities 
of CD14+ cells were not affected by atorvastatin at concentration up to 1 
μM (Figure 7C).  
 
Effect of atorvastatin on tumor necrosis factor-α-induced signal-
transduction pathways in FLSs from rheumatoid arthritis 
patients  
To investigate the mechanism by which atorvastatin suppresses the 
expression of TNF-α-induced RANKL, we examined its effects on the 
phosphorylations of p38 MAPK, JNK, ERK, and Akt. Western blotting 
revealed that atorvastatin inhibited TNF-α-induced p38 phosphorylation 
after 12 hours, but that it did not affect the phosphorylations of JNK, 
ERK, and Akt (Figure 8A). When we pretreated cells with SB203580 (a 
p38 inhibitor), TNF-α-induced RANKL mRNA expression was 
decreased, which was similar to the suppression of RANKL mRNA 
expression by atorvastatin (Figure 8B). We also measured soluble 
RANKL levels in FLSs culture media, and we found that its levels were 




Inhibition of osteoclast formation 
It was reported that RANKL is produced by RA FLS. We added 1,25-
dihydroxyvitamin D3 and M-CSF to media in which FLSs or cocultured 
cells were grown, according to a previously described method [3]. We 
could produce functionally active osteoclasts, and they were determined 
by TRAP staining (Figure 9A). When atorvastatin was added to 
cocultures of PBMCs and FLSs for 3 weeks, atorvastatin at ≥0.01 μM 
significantly decreased the numbers of TRAP-positive multinucleated 
osteoclasts (P < 0.01 versus control) (Figure 9A, B). To ensure that the 
inhibitory effect of atorvastatin on osteoclast formation was not due to 
an effect on cell viability, we performed MTT assay. Cell viabilities 
were assayed in separate cultures of FLSs and PBMCs. The viability of 
PBMCs after 3 weeks of treatment in the presence of M-CSF was not 
affected by atorvastatin (Figure 9C). Furthermore, atorvastatin had no 
effect on FLS viability after 3 weeks of treatment in the presence of 












Table 1. Clinical characteristics of the patients with RA. 
Patient     Disease duration    Site of surgery     Gender                  Medication 
       (month) 
 
1             180                 Knee         female      prednisolone 5 mg/d, celecoxib 200 mg/d, gasmotine 2.5 mg/d 
2             36                   Knee         female       cyclosporin A 100 mg/d, triamcinolone 2 mg/d 
3             240                  Knee         male     prednisolone 5 mg/d, hydroxychloroquine 200 mg/d, sulfasalazine  
                              500 mg/d 
4             180                  Hip          female       hydroxychloroquine 200 mg/d 
5             187                  Knee         female       deflazacort 5 mg/d, methotrexate 12.5 mg/d, leflunomide 10 mg/d, 
 
 Age of the patients was 53.0 ± 10.9 years (mean ± SD, range 35 to 63 years).  








Figure 1. Effects of atorvastatin on receptor activator of nuclear factor κB 
ligand (RANKL) expression in fibroblast-like synoviocytes (FLSs) from 
rheumatoid arthritis (RA) patients. FLSs were isolated from three RA patients 
(patient’s number 1, 2 and 3) and cultured in the presence of TNF-α (20 ng/ml) 
with or without atorvastatin for 24 hours. RANKL expressions were analyzed 
by RT-PCR (A), real-time PCR (B) and western blotting (C). D, TNF-α induced 
expression of RANKL mRNA in the FLSs of RA patients. Total RNA was 
extracted from FLSs cultured in the absence (-) or in the presence (+) of TNF-α 
(20 ng/ml) for indicated times. Total RNA was analyzed by RT-PCR. Results 






Figure 2. Effects of simvastatin on receptor activator of nuclear factor κB 
ligand (RANKL) expression in fibroblast-like synoviocytes (FLSs) from 
rheumatoid arthritis (RA) patients (patient’s number 1, 2 and 3). FLSs were 
isolated from three RA patients and cultured in the presence of TNF-α (20 
ng/ml) with or without simvastatin (10-100 μM) for 24 hours. RANKL 














Figure 3. Effects of mevalonate on the statin-induced suppression of RANKL. 
FLSs from RA patients (patient’s number 1, 2 and 3) were cultured in the 
presence of TNF-α (20 ng/ml), and then atorvastatin (50-100 μM) and 
mevalonate (100 μM) were added for 24 hours. RANKL expressions were 
analyzed by RT-PCR (A) and western blotting (B). A representative experiment 














Figure 4. Effects of mevalonate on the statin-induced suppression of RANKL. 
FLSs from RA patients (patient’s number 1, 2 and 3) were cultured in the 
presence of TNF-α (20 ng/ml), and then simvastatin (50-100 μM) and 
mevalonate (100 μM) were added for 24 hours. RANKL expressions were 














Figure 5. The effects of atorvastatin on cell viability and apoptosis. A, Effects 
of atorvastatin on the viability of FLSs from a RA patient (patient’s number 1, 2 
and 3). Cells were cultured for 24 hours in the presence of TNF-α (20 ng/ml) 
and atorvastatin at different concentration (10-100 μM). Cell viabilities were 
determined using MTT assays. B, Effects of atorvastatin on the apoptosis of 
















Figure 6. The effects of simvastatin on cell viability and apoptosis. A, Effects 
of simvastatin on the viability of FLSs from a RA patient (patient’s number 1, 2 
and 3). Cells were cultured for 24 hours in the presence of TNF-α (20 ng/ml) 
and simvastatin at different concentration (10-100 μM). Cell viabilities were 
determined using MTT assays. B, Effects of simvastatin on the apoptosis of 












Figure 7. Effects of atorvastatin on osteoprotegerin (OPG) expression in FLSs and 
RANK expression in CD14+ cells of RA patients (patient’s number 1, 4 and 5). A, RT-
PCR was used to analyze OPG mRNA expression in FLSs cultured for 24 hours with 
20 ng/ml TNF-α and atorvastatin (10-100 μM). The results shown are representative 
of three independent experiments. B, CD14+ cells were cultured for 48 or 72 hours in 
the presence of 2 ng/ml of macrophage colony-stimulating factor and different 
concentration of atorvastatin (0.01-1 μM). RANK mRNA expression was not affected 
by atorvastatin according to RT-PCR results. C, Atorvastatin had no effect on viability 


































Figure 8. The effect of atorvastatin on the phosphorylations of ERK, JNK, Akt and 
p38 MAPK, induced by TNF-α in FLSs from RA patients (patient’s number 1, 4 and 
5). A, FLSs were cultured in the presence of TNF-α (20 ng/ml) with or without 
atorvastatin (50-100 μM) for 24 hours to determine the effect of atorvastatin on the 
activations of signaling molecules. Phosphorylated ERK, JNK, Akt and p38 MAPK 
were analyzed using western blotting. Representative western blots from three 
independent experiments are shown. B, The effect of atorvastatin on the 
phosphorylation of p38 MARK induced by TNF-α in FLSs from an RA patient. After 
serum deprivation for 24 hours, FLSs were cultured with SB203580 (10 μM) for 2 
hours. TNF-α (20 ng/ml) and atorvastatin (50-100 μM) were then added and 
incubation was continued for another 24 hours. The expressions of RANKL mRNA 
relative to GAPDH were determined RT-PCR. C, RANKL secretion was determined 




































Figure 9. Effect of atorvastatin on osteoclast formation. A, Osteoclast formation was 
assayed by tartrate-resistant acid phosphatase (TRAP) staining and counting positive 
cells containing three or more nuclei under a light microscope (original magnification 
× 100). B, Peripheral blood mononuclear cells (PBMCs; 2×105cells/well) from a 
healthy donor were cocultured with fibroblast-like synoviocytes from a rheumatoid 
arthritis patient (RA-FLSs; 2×104cells/well, patient’s number 1, 4 and 5) in the 
presence of macrophage colony-stimulating factor, 1,25-dihydroxyvitamin D3, and 
different concentrations (0.001-0.1 μM) of atorvastatin in 96-well plates for 3 weeks. 
Cell viabilities were assayed in separate cultures of FLSs and PBMCs. C, PBMCs 
were cultured for 3 weeks in the presence of 10-7 M 1,25-dihydroxyvitamin D3 and 
different concentrations of atorvastatin. D, RA-FLSs were cultured for 3 weeks in the 
presence of 2 ng/ml macrophage colony-stimulating factor and different 
concentrations of atorvastatin (0.001-0.1 μM). Bars represent means and SDs. All 
















Statins inhibit the rate-limiting step of cholesterol synthesis by preventing 
HMG-CoA from being reduced to mevalonate by HMG-CoA reductase. [21] 
In addition, statins appear to have beneficial therapeutic effects on several 
human diseases, such as, multiple sclerosis (MS) [22] and osteoporosis [23], 
which have no direct association with cholesterol levels. Recently, a number 
of reports have been issued on the anti-inflammatory potentials of statins in 
rheumatic disease [18, 19, 24, 25] Therefore, we hypothesized that 
atorvastatin could have beneficial effects on the progressive joint destruction 
in RA. In a preliminary study, we confirmed that TNF-α induced RANKL in 
FLSs from RA patients after incubation for 24 hours, which is consistent with 
that found by Kubota A et al [26]. In the present study, we found that 
atorvastatin inhibited the expression of TNF-α induced RANKL in FLSs from 
RA patients. Simvastatin also significantly and dose-dependently inhibited the 
expression of RANKL mRNA and protein in the FLSs of RA patients. 
Mevalonate is not only a substrate for cholesterol biosynthesis, it is also 
required for the synthesis of several other biologically important lipid 
intermediates by means of alternative synthesis pathway [27]. Furthermore, it 
is well known that mevalonate prevents the effects of statins, and in the 
present study, we found that the suppression of RANKL expression by statins 
was prevented by mevalonate. Osteoclasts play an important role in 




in differentiation of osteoclasts from their precursor cells and promotes the 
activity and survival of these cells, which leads to bone resorption [31]. In the 
present study, the results were obtained using coculture system for 
osteoclatogenesis and showed that atorvastatin inhibits osteoclast formation. 
To our knowledge, this is the first report describing that atorvastatin inhibits 
osteoclastogenesis by attenuating RANKL expression in the FLSs of RA. In 
the present study, we performed cocultures at lower atorvastatin 
concentrations (0.001-0.1 μM). Exposure to higher concentrations (1 μM or 
more) for 3 weeks was found to be toxic to both FLSs and PBMCs (data not 
shown). 
 The receptor activator of the NF- κB (RANK)/RANKL system has been 
shown to be a critical factor during osteoclast differentiation and bone 
resorption [31-33]. In addition, osteoprotegerin (OPG) functions as a high-
affinity soluble decoy receptor for RANKL and competes with RANK for 
RANKL binding. Therefore, OPG is an effective inhibitor of the RANK-
RANKL interaction. Several research groups have assessed the role of the 
RANK/RANKL/OPG system in RA, and experimental arthritis models have 
been established to study the in vivo effects of these molecules [4]. Recently, 
RANKL was reported to participate in osteoclast formation in a model of 
spontaneously developing erosive arthritis in the mouse [30]. However, in the 
present study, atorvastatin did not enhance the expressions of OPG protein 
and mRNA, and atorvastatin did not affect RANK expression in CD14+ cells. 
These findings indicate that the inhibition of osteoclast formation by 




Signaling pathways that regulate proinflammatory mediator expression in 
FLSs of RA patients include MAPKs and NF-κB. Three MAPK families have 
been implicated in RA, namely, ERK1/2, JNK and p38 MAPK [34]. 
Interestingly, all three of these MAPK families are activated in RA synovial 
tissue and in cultured FLSs from RA patients. Furthermore, TNF-α has the 
potential to signal through all three [35]. However, we observed atorvastatin 
decreased the phosphorylation of p38 but not those of ERK 1/2 or JNK, and 
that SB203580 (a specific p38 inhibitor) had a similar inhibitory effect on 
RANKL production in the FLSs of RA patients. Therefore p38 may play a 




















The present study shows that atorvastatin markedly reduce RANKL 
expression in the fibroblast-like synoviocytes of rheumatoid arthritis patients 
and atorvastatin inhibits osteoclastogenesis in co-cultures of PBMCs and 
FLSs. These results suggest that atorvastatin may inhibit osteoclastogenesis 
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국   
Statin  hydroxymethylglutaryl 코엔자임 원효소 억 , 
항염증과 면역조  효과를 갖는 것  보고 어 있다. 그리고  
collagen 발 마티스 염 동 모델에  방  료  효
과가 보고 었다. 본 연구에 는 마티스 염 자  
모 포양 막 포에  osteoprotegerin (OPG) 과 receptor activator 
of nuclear factor κB ligand (RANKL)  발 에 한 atorvastatin  
효과   조사하 다. 또한 atorvastatin이 골 포 분 를 
억 하는지 밝히고자 하 다.  
 
5명  마티스 염 자 부터 얻  모 포양 막
포를 배양하 고, TNF-α 를 20 ng/ml 과 atorvastatin  첨가한 
후 첨가하지 않  군과 western blotting 과 enzyme-linked 
immunosorbent assay   실험하 다. 골 포  말
액 단핵 포  모 포양 막 포를 공동 배양하여 
tartrate-resistant acid phosphatase (TRAP) 염색 후 다핵 골 포 
를 어 하 다. 
 
Atorvastatin  모 포양 막 포에  용량 존




mevalonate에 해  RANKL  발  억 를 막았다. 그러나 
atorvastatin  모 포양 막 포에  OPG  발 에는 향
 주지 않았고, CD14+ 포에  RANK  발 에도 향  주
지 않았다. 
Atorvastatin  모 포양 막 포에  TNF-α에 해 도  
p38 인산 를 억 하 다. Atorvastatin  단핵 포  모 포 
양 막 포를 공동 배양하  때, TRAP 양  포이면  다 
핵 포인 골 포  를 하게 감소시켰다. 
 
이러한 결과는 atorvastatin이 마티스 염 자에  골
포분  골 를 억 함  시사하 다. 
 
이 연구는 Arthritis Research & Therapy 잡지에 게재 었다. 
(Arthritis Research & Therapy 2012 Aug 17;14(4):R187). 
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